** Shares of drug developer Adial Pharmaceuticals ADIL.O rise as much as 68.8% to $1.30
** ADIL says U.S. FDA agreed with co's plan to use a specific approach called "in vitro bridging strategy" to support the development of AD04, to treat alcohol-use disorder in heavy-drinking patients
** This approach involves using existing data and lab tests to show that the new version of AD04 is equivalent to the previous version
** Co is developing the drug for its upcoming late-stage trial, set to begin this year
** Last year, AD04 showed safety and tolerability consistent with an existing treatment
** ADIL fell 42.3% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。